bioAffinity Technologies Secures Australian Patent for Lung Disease Detection Platform
ByAinvest
Tuesday, Oct 28, 2025 8:01 am ET1min read
BIAF--
bioAffinity Technologies has announced the acceptance of an Australian patent application for its platform technology to detect and characterize multiple lung diseases. The patent application covers methods using flow cytometry to reveal disease-related changes across multiple cell types in a sputum sample. This innovation has the potential to lead to new diagnostic tools for personalized lung health. The Australian patent complements existing intellectual property protection in the US and other international jurisdictions, strengthening the company's global patent portfolio.
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
Comments
No comments yet